Heartflow Q3 revenue $46.3M (+41% YoY); initiates FY2025 guidance $173.0M-$173.5M

Heartflow, Inc.

2025-Q3 EPS reported -$4.47 revenue$126,904,000

Net loss $50.9M ($1.04/share) includes $32.1M warrant remeasurement; non-GAAP net loss $13.2M ($0.27/share).
Gross margin 76.5% (non-GAAP 76.8%); net operating loss $15.1M (non-GAAP $11.1M).
UnitedHealthcare and Cigna began covering Heartflow Plaque Analysis on Oct 1, 2025.
IPO raised ~$364.2M in gross proceeds; cash $291.2M at Sept 30 after debt repayments.
Full year 2025 revenue guidance $173.0M-$173.5M; warrants fully exercised post-quarter.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.